Management of blood glucose with noninsulin therapies in type 2 diabetes

American Family Physician

Volumn 92, Issue 1, 2015, Pages 27-34

  George, Christa M ^a   Bruijn, Lucy L ^a   Will, Kayley ^b   Howard Thompson, Amanda ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALBIGLUTIDE; ALOGLIPTIN; CANAGLIFLOZIN; CREATININE; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DAPAGLIFLOZIN; DULAGLUTIDE; EMPAGLIFLOZIN; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; TRIACYLGLYCEROL; UNINDEXED DRUG; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ARTICLE; BLOATING; BLOOD GLUCOSE MONITORING; BODY WEIGHT DISORDER; CARDIOVASCULAR RISK; DIARRHEA; DIET THERAPY; EDEMA; EXERCISE; FLATULENCE; GENITAL TRACT INFECTION; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; MULTICENTER STUDY (TOPIC); NAUSEA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); URINARY TRACT INFECTION; ADULT; CLASSIFICATION; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; MEDICATION THERAPY MANAGEMENT; MOTOR ACTIVITY; PRACTICE GUIDELINE; PROCEDURES; PSYCHOLOGY; QUALITY OF LIFE;

ADULT; BLOOD GLUCOSE SELF-MONITORING; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIET THERAPY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MEDICATION THERAPY MANAGEMENT; MOTOR ACTIVITY; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84936061358     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care. 2014;37(suppl 1):S14-S80.
2. Evert AB, Boucher JL, Cypress M, et al. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care. 2014; 37(suppl 1):S120-S143.
3. Pi-Sunyer X, Blackburn G, Brancati FL, et al. ; Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007;30(6):1374-1383.
4. Raynor HA, Jeffery RW, Ruggiero AM, Clark JM, Delahanty LM; Look AHEAD Research Group. Weight loss strategies associated with BMI in overweight adults with type 2 diabetes at entry into the Look AHEAD (Action for Health in Diabetes) trial. Diabetes Care. 2008;31(7):1299-1304.
5. Evert AB, Boucher JL, Cypress M, et al. ; American Diabetes Association. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care. 2013;36(11):3821-3842.
6. Wing RR, Bolin P, Brancati FL, et al. ; Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes [published correction appears in N Engl J Med. 2014;370(19):1866]. N Engl J Med. 2013;369(2):145-154.
7. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group [published correction appears in Lancet. 1998;352(9139):1558]. Lancet. 1998;352(9131):854-865.
8. Bennett WL, Wilson LM, Bolen S, et al. Oral diabetes medications for adults with type 2 diabetes: an update. AHRQ Comparative Effectiveness Review, no. 27. AHRQ publication no. 11-EHC038-EF. Rockville, Md. : Agency for Healthcare Research and Quality; March 2011.
9. Powers AC, D'Alessio D. Chapter 43. Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglycemia. In: Brunton LL, Chabner BA, Knollmann BC, eds. Goodman & Gilman's Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill; 2011.
10. Lexicomp. Hudson, Ohio: American Pharmacists Association. http:// online. lexi. com/crlsql/servlet/crlonline. Accessed January 3, 2015.
11. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589.
12. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [published correction appears in Diabetes Care. 2013;36(2):490]. Diabetes Care. 2012;35(6):1364-1379.
13. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1-150.
14. Micromedex Solutions. Metformin hydrochloride. http://www. micro medex solutions. com. ezproxy. uthsc. edu. Accessed October 10, 2014.
15. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;(4):CD002967.
16. Micromedex Solutions. Glyburide. http://www. micro medex solutions. com. ezproxy. uthsc. edu. Accessed October 10, 2014.
17. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970;19(suppl 2):789-830.
18. Holden SE, Currie CJ. Mortality risk with sulphonylureas compared to metformin. Diabetes Obes Metab. 2014;16(10):885-890.
19. Hemmingsen B, Schroll JB, Lund SS, et al. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2013;4:CD009008.
20. Micromedex Solutions. Sitagliptin phosphate. http://www. micromedex solutions. com. ezproxy. uthsc. edu. Accessed July 7, 2014.
21. Home PD, Pocock SJ, Beck-Nielsen H, et al. ; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125-2135.
22. U. S. Food and Drug Administration. FDA drug safety communication: update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer. http://www. fda. gov/drugs/drugsafety/ucm 259150. htm. Accessed May 1, 2015.
23. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011;34(4):916-922.
24. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia. 2012;55(7):1953-1962.
25. Kahn SE, Zinman B, Lachin JM, et al. ; Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008;31(5):845-851.
26. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009;180(1):32-39.
27. Aubert RE, Herrera V, Chen W, Haffner SM, Pendergrass M. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes Metab. 2010;12(8):716-721.
28. Bazelier MT, Gallagher AM, van Staa TP, et al. Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs? Pharmacoepidemiol Drug Saf. 2012;21(5):507-514.
29. Micromedex Solutions. Exenatide. http://www. micromedexsolutions. com. ezproxy. uthsc. edu. Accessed July 9, 2014.
30. Micromedex Solutions. Pramlintide acetate. http://www. micromedex solutions. com. ezproxy. uthsc. edu. Accessed July 8, 2014.
31. Micromedex Solutions. Canagliflozin. http://www. micromedexsolutions. com. ezproxy. uthsc. edu. Accessed July 9, 2014.
32. Garber AJ, Abrahamson MJ, Barzilay JI, et al. ; American Association of Clinical Endocrinologists. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19(2):327-336.
33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [published correction appears in Lancet. 1999;354(9178):602]. Lancet. 1998;352(9131):837-853.
34. Implications of the United Kingdom Prospective Diabetes Study. American Diabetes Association. Diabetes Care. 1998;21(12):2180-2184.
35. Ewart RM. The case against aggressive treatment of type 2 diabetes: critique of the UK prospective diabetes study. BMJ. 2001;323(7317): 854-858.
36. McCormack J, Greenhalgh T. Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. BMJ. 2000;320(7251):1720-1723.
37. Shaughnessy AF, Slawson DC. What happened to the valid POEMs? A survey of review articles on the treatment of type 2 diabetes. BMJ. 2003;327(7409):266.
38. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412.
39. Gerstein HC, Miller ME, Byington RP, et al. ; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
40. Patel A, MacMahon S, Chalmers J, et al. ; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.
41. Duckworth W, Abraira C, Moritz T, et al. ; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes [published correction appears in N Engl J Med. 2009;361(10):1028]. N Engl J Med. 2009;360(2):129-139.
42. Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ. 2011;343:d6898.
43. Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;375(9713):481-489.
44. Malanda UL, Welschen LM, Riphagen II, Dekker JM, Nijpels G, Bot SD. Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin. Cochrane Database Syst Rev. 2012; (1):CD005060.
45. Farmer AJ, Perera R, Ward A, et al. Meta-analysis of individual patient data in randomised trials of self monitoring of blood glucose in people with non-insulin treated type 2 diabetes. BMJ. 2012;344:e486.